Dual Tumor Microenvironment Remodeling by Glucose-Contained Radical Copolymer for MRI-Guided Photoimmunotherapy.
Hongwei ChengXiaoshan FanEnyi YeHu ChenJing YangLingjie KeMingliang YouMinting LiuYong-Wei ZhangYun-Long WuGang LiuXian Jun LohZibiao LiPublished in: Advanced materials (Deerfield Beach, Fla.) (2021)
Aberrant glucose metabolism and immune evasion are recognized as two hallmarks of cancer, which contribute to poor treatment efficiency and tumor progression. Herein, a novel material system consisting of a glucose and TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxyl) at the distal ends of PEO-b-PLLA block copolymer (glucose-PEO-b-PLLA-TEMPO), is designed to encapsulate clinical therapeutics CUDC101 and photosensitizer IR780. The specific core-shell rod structure formed by the designed copolymer renders TEMPO radicals excellent stability against reduction-induced magnetic resonance imaging (MRI) silence. Tumor-targeting moiety endowed by glucose provides the radical copolymer outstanding multimodal imaging capabilities, including MRI, photoacoustic imaging, and fluorescence imaging. Efficient delivery of CUDC101 and IR780 is achieved to synergize the antitumor immune activation through IR780-mediated photodynamic therapy (PDT) and CUDC101-triggered CD47 inhibition, showing M1 phenotype polarization of tumor-associated macrophages (TAMs). More intriguingly, this study demonstrates PDT-stimulated p53 can also re-educate TAMs, providing a combined strategy of using dual tumor microenvironment remodeling to achieve the synergistic effect in the transition from cold immunosuppressive to hot immunoresponsive tumor microenvironment.
Keyphrases
- photodynamic therapy
- fluorescence imaging
- magnetic resonance imaging
- contrast enhanced
- blood glucose
- diffusion weighted imaging
- drug release
- high resolution
- computed tomography
- papillary thyroid
- magnetic resonance
- small molecule
- type diabetes
- minimally invasive
- oxidative stress
- long non coding rna
- endothelial cells
- young adults
- smoking cessation
- combination therapy
- lymph node metastasis
- glycemic control